The role of antifibrotics in the treatment of rheumatoid arthritis associated interstitial lung disease
Liang M, Matteson EL, Abril A, Distler J (2022)
Publication Type: Journal article, Review article
Publication year: 2022
Journal
Book Volume: 14
DOI: 10.1177/1759720X221074457
Abstract
The major pulmonary complication of rheumatoid arthritis (RA) is interstitial lung disease (ILD), which causes significant morbidity and mortality and influences the natural course of disease. Recent advances in the management of arthritis have improved patient outcomes. However, exceptionally high medical needs still remain for effective therapies for the patients with ILD in RA. Better understanding of the shared and distinct pathophysiology of fibrotic diseases led to the development of novel antifibrotic agents such as nintedanib and pirfenidone. The further stratification analysis of the phase III INBUILD trial demonstrated beneficial effects of nintedanib in RA-ILD with a progressive phenotype by reducing the rate of decline in forced vital capacity (FVC) over 52weeks by 60%. Pirfenidone is another antifibrotic agent currently under phase II clinical study (TRAIL1) aiming to evaluate its effects for RA-ILD. This review provides an overview of state-of-the-art pathogenesis and the current therapeutic options for RA-ILD, with a focus on antifibrotic strategies.
Authors with CRIS profile
Involved external institutions
United States (USA) (US)How to cite
APA:
Liang, M., Matteson, E.L., Abril, A., & Distler, J. (2022). The role of antifibrotics in the treatment of rheumatoid arthritis associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 14. https://doi.org/10.1177/1759720X221074457
MLA:
Liang, Minrui, et al. "The role of antifibrotics in the treatment of rheumatoid arthritis associated interstitial lung disease." Therapeutic Advances in Musculoskeletal Disease 14 (2022).
BibTeX: Download